Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation.
Options
BORIS DOI
Publisher DOI
PubMed ID
37694381
Description
INTRODUCTION
Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment.
AREAS COVERED
Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses.
EXPERT OPINION
IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.
Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment.
AREAS COVERED
Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses.
EXPERT OPINION
IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.
Date of Publication
2023-09-11
Publication Type
Article
Subject(s)
Keyword(s)
25 years Interferon beta-1a disease-modifying therapy generation long-term efficacy long-term safety mechanisms of action multiple sclerosis
Language(s)
en
Contributor(s)
Zettl, Uwe Klaus | |
Rommer, Paulus Stefan | |
Aktas, Orhan | |
Wagner, Torsten | |
Richter, Joachim | |
Oschmann, Patrick | |
Cepek, Lukas | |
Elias-Hamp, Birte | |
Gehring, Klaus | |
Hecker, Michael |
Additional Credits
Series
Expert review of clinical immunology
Publisher
Taylor & Francis
ISSN
1744-8409
Access(Rights)
open.access